NON-IND, IRB-APPROVED CLINICAL STUDIES

Axcella Provides Progress Updates for Liver Program Candidates AXA1125 and AXA1957

Retrieved on: 
Monday, October 7, 2019
Research, Infectious diseases, Clinical trials, Biotechnology, Pharmaceutical, Health, Science, Liver disease, Endogenous Metabolic Modulators, Non-IND, IRB-Approved Clinical Studies, Axcella Health

Axcella Health Inc. , (Nasdaq: AXLA) (Axcella or the Company) a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced liver program progress updates regarding the development of AXA1125 and AXA1957.

Key Points: 
  • Axcella Health Inc. , (Nasdaq: AXLA) (Axcella or the Company) a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced liver program progress updates regarding the development of AXA1125 and AXA1957.
  • AXA1125 and AXA1957 are novel compositions of endogenous metabolic modulators (EMMs) designed to simultaneously support metabolic, inflammatory and fibrotic pathways associated with liver health.
  • Given the significant unmet need, the data generated to date and the potential of multifactorial interventions such as EMMs in liver disease, Axcella will be developing AXA1125 and AXA1957 as therapeutic candidates in NASH under an IND.
  • Axcellas AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood.

Axcella Announces Presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting

Retrieved on: 
Tuesday, October 1, 2019
Biotechnology, Pharmaceutical, Health, Medical specialties, Anatomy, Hepatitis, Medicine, Non-alcoholic fatty liver disease, Fatty liver disease, Liver disease, Alcoholic liver disease, Endogenous Metabolic Modulators, Non-IND, IRB-Approved Clinical Studies, Axcella Health

The continued selection of abstracts at major international conferences represents Axcellas progress in developing endogenous metabolic modulators (EMMs).

Key Points: 
  • The continued selection of abstracts at major international conferences represents Axcellas progress in developing endogenous metabolic modulators (EMMs).
  • AXA1125, currently in a Non-IND, IRB-Approved Clinical Study in adult subjects with non-alcoholic fatty liver disease (NAFLD), is a novel composition of EMMs designed to simultaneously support metabolic, inflammatory and fibrotic pathways associated with liver health.
  • Our AXA Candidates are anchored by EMMs that have a history of safe use as food.
  • If Axcella decides to further develop an AXA Candidate as a potential therapeutic, subsequent studies will be conducted under an IND.